Government representatives from Australia and the United Kingdom have agreed to keep cooperating across the life sciences, from laboratory research through to regulation and commercial launch, according to a joint statement published on GOV.UK. The agreement followed a meeting in Canberra on 15 September 2026. Both sides linked the decision to better patient health, investment, innovation-led growth and the creation of high-value jobs.
The statement names the fields where the two countries intend to deepen ties. These are clinical trials, genomics and precision medicine, digital health, advanced therapies, biotechnology innovation, regulatory excellence and the routes by which new products reach the market. Life sciences have been a named bilateral innovation priority since April 2024, when the first Strategic Innovation Dialogue took place in London.
Nuclear medicine and cell therapy
Some of the most concrete work described involves radiopharmaceuticals. Under InnovateUK's Sustainable Medicines Manufacturing Innovation programme, the Medicines Discovery Catapult is working with Australian partners. Its goals are to secure supplies of lead-212 and to speed up targeted alpha therapies. With help from AUScelerate, it has also partnered with entX, whose nuclear medicine brand Isomedica is developing technologies to recover isotopes from low-level radioactive waste. According to the statement, the partnership has supplied the Catapult with material for cancer-related radiotherapy research.
The Cell and Gene Therapy Catapult has helped an Australian maker of cell therapy production systems demonstrate its technology in the UK. It also assessed the economic case and market prospects for an Australian university team working on a stem cell therapy for heart failure.
Regulators
The statement points to agreements between Australia's Therapeutic Goods Administration (TGA) and the UK's Medicines and Healthcare products Regulatory Agency (MHRA) that let the two bodies share assessment work and information. Both also sit in the Access Consortium with authorities from Canada, Singapore and Switzerland. The statement says joint reviews in that group reduce duplicated effort and help patients get safe medicines in good time. The agencies also backed continued implementation of a bilateral mutual recognition agreement on conformity assessment for medical devices.
Trade and industry links
- 16 June 2025: AusBiotech and the UK BioIndustry Association (BIA) hosted a bilateral biotech roundtable at the BIO International Convention in Boston. The statement says the two groups signed a memorandum of understanding on policy alignment and industry collaboration.
- October 2025: AusBiotech, the Medicines Discovery Catapult and the British Trade Consul gathered stakeholders at the AusBiotech International Conference.
- May 2026: Austrade held two Australian Clinical Trials Initiative seminars, at Australia House in London and Milton Park in Oxfordshire, together with BioUK, One Nucleus and AusBiotech.
AusBiotech has also commissioned a guide to UK regulation for Australian biotech firms. The statement lists indicative participants that remain committed to the effort. They include the National Health and Medical Research Council, the Medical Research Future Fund, Brandon Capital and the National Institute for Health and Care Research.






